Carboxamides (i.e., R-c(=o)-n, Wherein R Is A Radical Having Carbon Bonded Directly To The C(=o)-n Or Is Hydrogen And Wherein Any Substituent Attached To Nitrogen Will Be Referred To As E) Patents (Class 514/613)
  • Patent number: 8748661
    Abstract: The present invention relates to novel polyamino polyketide antibiotics, methods of their production as well as methods of using these antibiotics, for example, for inhibition or removal of biofilm formation or for treating bacterial infection with these antibiotics.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: June 10, 2014
    Assignee: Agency for Science, Technology and Research
    Inventors: Jien Wu, Haibao Zhang, Lianhui Zhang
  • Patent number: 8747875
    Abstract: An insecticidal composition comprising stabilized pyrethrins or pyrethroids is provided. Such composition includes stabilizing effective amount of N,N-dialkyl fatty acid amide solvents and certain ultraviolet-light absorbers. In such composition, the pyrethrins or pyrethroid can retain their insecticidal activity for an acceptably long period of time. Therefore, an advantage of this invention is to provide a topical pyrethrins or pyrethroid based insecticide which can remain effective in light over a long time period. Another advantage of this invention is to provide a stabilized topical pyrethrins or pyrethroid insecticide insecticidal formulation containing a high concentration of the active pyrethrins or pyrethroid ingredient to minimize the volume of formulation required.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: June 10, 2014
    Assignee: The Hartz Mountain Corporation
    Inventors: W. Lance H. Hemsarth, Linda Valencia
  • Publication number: 20140155487
    Abstract: The present invention relates to methods for the treatment of a disease or condition associated with lipid imbalance using fenretinide. The invention also relates to diagnostic and screening methods based on the determination of lipid levels.
    Type: Application
    Filed: February 5, 2014
    Publication date: June 5, 2014
    Applicant: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
    Inventors: Danuta RADZIOCH, Claudine GUILBAULT, Juan Bautista DE SANCTIS
  • Patent number: 8741967
    Abstract: The present invention is directed to unsaturated sphingosine compounds which are useful as therapeutic agents for the treatment of cancer and for the treatment of other diseases including diabetes and infection with intracellular bacteria. This invention is also directed to methods of using the compounds and pharmaceutical compositions comprising the compounds in treating these diseases.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: June 3, 2014
    Assignees: Children's Hospital & Research Center at Oakland, Research Foundation of the City University of New York
    Inventors: Julie D. Saba, Henrik Fyrst, Robert Bittman
  • Patent number: 8741324
    Abstract: The present invention relates to liquid pesticide concentrate compositions which comprise at least one organic pesticide compound that is sparingly or even insoluble in water and which upon dilution with water form stable aqueous nanoparticulate formulations. The liquid pesticide concentrate compositions of the invention comprise: a) at least one organic pesticide compound C having a water solubility of not more than 1 g/l at 25° C./1013 mbar, b) at least one organic solvent S having a water solubility at least 10 g/l at 25° C.
    Type: Grant
    Filed: July 5, 2005
    Date of Patent: June 3, 2014
    Assignee: BASF SE
    Inventors: Charles W. Finch, Thomas Byrne, Hassan Oloumi-Sadeghi
  • Patent number: 8728522
    Abstract: Methods and compositions are provided which comprise effective amounts of one or more analgesics, such as hydrocodone or acetaminophen, and an antiemetic, such as promethazine, to treat a subject, including reducing or eliminating an adverse effect associated with the analgesics.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: May 20, 2014
    Assignee: Charleston Laboratories, Inc.
    Inventors: Paul Bosse, John Ameling, Bernard Schachtel, Ray Takigiku
  • Patent number: 8729131
    Abstract: The present invention relates to an agomelatine hydrochloride hydrate of formula I, preparation and use thereof, and to pharmaceutical composition containing it. The agomelatine hydrohalide hydrate obtained through the present method has significant increased solubility than agomelatine, and therefore is more suitable for manufacturing pharmaceutical formulations. In addition, the product enjoys higher stability and purity. Using the present method, product of high purity can be obtained through a simple process, free of any complicated steps. wherein X is Cl.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: May 20, 2014
    Assignee: Les Laboratoires Servier
    Inventors: Hanbin Shan, Zhedong Yuan, Xueyan Zhu, Peng Zhang, Hongjuan Pan, Xiong Yu
  • Patent number: 8729132
    Abstract: The present invention relates to an agomelatine hydrobromide hydrate of formula I wherein X is Br, preparation and use thereof, and to pharmaceutical compositions containing it. The agomelatine hydrobromide hydrate obtained through the present method has significant increased solubility than agomelatine, and therefore is more suitable for manufacturing pharmaceutical formulations. In addition, the product enjoys higher stability and purity. Using the present method, product of high purity can be obtained through a simple process, free of any complicated steps.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: May 20, 2014
    Assignee: Les Laboratoires Servier
    Inventors: Hanbin Shan, Zhedong Yuan, Xueyan Zhu, Peng Zhang, Hongjuan Pan, Xiong Yu
  • Publication number: 20140134113
    Abstract: Suggested is a pharmaceutical composition, comprising menthane carboxylic acid-N-(4-methoxy-phenyl)-amide.
    Type: Application
    Filed: November 8, 2013
    Publication date: May 15, 2014
    Applicant: Symrise AG
    Inventors: Gerhard Krammer, Sven Siegel, Silke Middendorf
  • Patent number: 8716527
    Abstract: Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2- substituted-p-quinone derivatives as disclosed herein.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: May 6, 2014
    Assignee: Edison Pharmaceuticals, Inc.
    Inventors: Andrew W. Hinman, Kieron E. Wesson, Orion D. Jankowski, Paul Mollard, William D. Shrader, Christopher R. Cornell
  • Publication number: 20140121217
    Abstract: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein A, Y, L, R1, W1 and W2 are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Application
    Filed: January 2, 2014
    Publication date: May 1, 2014
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Lijun Sun, Jun Jiang, Yu Xie
  • Patent number: 8709379
    Abstract: Formulations of neutral retinoids, in particular fenretinide (HPR) in the form of lipid nanoparticles, solid dispersions and emulsions are disclosed. These compositions are used to treat diseases that are amenable to treatment by HPR, such as neoplastic diseases by achieving higher and more prolonged concentrations of HPR in the subject. The key steps for preparing lipid nanovesicles of HPR include mixing and sonication, sterile filtration, without or without lyophilization for long-term stable storage, and employ processes and materials that are scalable from the laboratory to the manufacturing level. The formulation are suitable for injection into human or animal patients without causing allergic or hypersensitivity responses by avoiding chemical surfactants and animal sources of phospholipids in their manufacture.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: April 29, 2014
    Assignee: Scitech Development, LLC
    Inventors: Ralph E. Parchment, Bhaskara R. Jasti, Ramesh R. Boinpally, Stephen E. Rose, Earle T. Holsapple
  • Publication number: 20140113973
    Abstract: Compounds, methods, uses, compositions, kits and packages for the prevention and/or treatment of neural injury or a neurodegenerative disease, based on the use of a retinoic acid derivative, such as fenretinide, and/or analogs, derivatives, prodrugs, precursors thereof, and/or salts thereof, are described.
    Type: Application
    Filed: December 23, 2013
    Publication date: April 24, 2014
    Applicant: Royal Institution for the Advancement of Learning/McGill University
    Inventors: Danuta Radzioch, Samuel David, Ruben Lopez-Vales, Thomas Skinner
  • Publication number: 20140107124
    Abstract: Disclosed herein are compositions comprising an amide related to a prostaglandin and a biogenic amine. Other aspects relate to certain chemical compounds, pharmaceutical compositions, and methods of treating glaucoma.
    Type: Application
    Filed: December 20, 2013
    Publication date: April 17, 2014
    Applicant: Allergan, Inc.
    Inventors: David F. Woodward, Robert M. Burk
  • Patent number: 8686044
    Abstract: An amide derivative represented by the following Formula (1) is provided as an amide derivative showing a significantly excellent effect for a pest control action. In the following Formula (1), A represents a carbon atom, a nitrogen atom, or the like, and K represents a non-metal atomic group necessary for forming a cyclic linking group derived from benzene or a heterocyclie. X represents a halogen atom or the like; n represents an integer of from 0 to 4. R1 and R2 represent hydrogen atoms, alkyl groups, or the like. T represents —C(=G1)-Q1 or —C(=G1)-G2Q2, and G1 to G3 each represent oxygen atoms or the like. Q1 and Q2 each represent a hydrogen atom, an alkyl group, an aryl group, or the like. Y1 and Y5 each represent a halogen atom or the like, Y2 and Y4 each represent a hydrogen atom or the like, and Y3 represents a C2-C5 haloalkyl group.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: April 1, 2014
    Assignee: Mitsui Chemicals Agro, Inc.
    Inventors: Yumi Kobayashi, Hidenori Daido, Hiroyuki Katsuta, Michikazu Nomura, Hidetaka Tsukada, Atsushi Hirabayashi, Yusuke Takahashi, Yoji Aoki, Atsuko Kawahara, Yasuaki Fukazawa, Mai Hirose
  • Publication number: 20140080802
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.
    Type: Application
    Filed: October 28, 2013
    Publication date: March 20, 2014
    Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen Haggarty, Yan-Ling Zhang
  • Patent number: 8673982
    Abstract: This invention relates to certain ceramide-analogues of FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol; fingolimod). In particular, the present invention relates to pharmaceutical compositions comprising these compounds, as well as processes for their preparation and their use in the treatment of autoimmune conditions, such as multiple sclerosis.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: March 18, 2014
    Assignee: Novartis AG
    Inventors: Volker Brinkmann, Guido Jordine, Markus Zollinger, Claudia Sayer
  • Patent number: 8673340
    Abstract: A scleral lens is provided with a sodium channel blocker or a sodium channel modulator disposed in the pre-corneal tear film between the scleral lens and the cornea. This system can be used to deliver sodium channel blockers or a sodium channel modulators not currently used because of poor bioavailability. Methods of using this sodium channel blocker delivery system or a sodium channel modulator delivery system are also disclosed.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: March 18, 2014
    Assignee: Boston Foundation for Sight
    Inventor: Perry Rosenthal
  • Patent number: 8664274
    Abstract: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pinchinde, and VSV), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: March 4, 2014
    Assignee: Siga Technologies, Inc.
    Inventors: Dongcheng Dai, Tove Bolken, Dennis E. Hruby, Thomas R. Bailey
  • Publication number: 20140056832
    Abstract: The present invention relates to the use of at least one 2-methylsuccinic acid diester derivative of formula (I), in a composition comprising, in a cosmetically acceptable medium, at least one liquid fatty phase and at least one lipophilic active agent, for dissolving the said active agent in the said liquid fatty phase and/or for improving the solubility of the said active agent in the said solid fatty phase. The present invention relates especially to a composition comprising, in a cosmetically acceptable medium, at least one liquid fatty phase, characterized in that it contains at least one 2-methylsuccinic acid ester derivative of formula (I) and at least one lipophilic active agent.
    Type: Application
    Filed: February 23, 2012
    Publication date: February 27, 2014
    Inventors: Herve Richard, Benoit Muller
  • Publication number: 20140056949
    Abstract: Formulations for chemoprevention of oral cancer and precancerous lesions, and for methods for preparing the formulations are described.
    Type: Application
    Filed: November 15, 2011
    Publication date: February 27, 2014
    Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, THE OHIO STATE UNIVERSITY
    Inventors: Susan R. Mallery, Peter E. Larsen, Gary D. Stoner, Steven P. Schwendeman, Kashappa-Goud Desai
  • Patent number: 8658697
    Abstract: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pinchinde, and VSV), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).
    Type: Grant
    Filed: October 26, 2010
    Date of Patent: February 25, 2014
    Assignee: Siga Technologies, Inc.
    Inventors: Dongcheng Dai, Tove Bolken, Dennis E. Hruby, Thomas R. Bailey
  • Patent number: 8653002
    Abstract: The present invention relates to aqueous suspension concentrate formulation for plant protection comprising: 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2H)pyrimidinyl]-4-fluoro-N-[[methyl(1-methylethyl)amino]sulfonyl]benzamide in the form of its crystalline anhydrate; at least one non-ionic surfactant selected from polyoxyethylene-polyoxy-C3-C4-alkylene block copolymers; at least one anionic surfactant comprising at least one arylsulfonate group; and water; wherein the pH value of the formulation is in the range of 3 to 7.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: February 18, 2014
    Assignee: BASF SE
    Inventors: Michael Krapp, Wolfgang Gregori, Klaus Kolb, Bernd Sievernich, Heidi Emilia Saxell, Joerg Steuerwald, Steven Bowe, Rex Liebl, Terrance M. Cannan
  • Patent number: 8653114
    Abstract: The present invention relates to O-CYCLOPROPYLCYCLOHEXYL-CARBOXANILIDES derivatives of formula (I); their process of preparation, their use as fungicide, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: February 18, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Jörg Nico Greul, Jürgen Benting, Peter Dahmen, Ulrike Wachendorff-Neumann
  • Publication number: 20140044737
    Abstract: Methods for screening molecules that modulate the activity of Retinol Binding Protein 4 (RBP4) and their use in treatment of insulin resistance are described. Also described are methods of diagnosing insulin resistance and related conditions by detecting modulation of RBP4 activity.
    Type: Application
    Filed: October 24, 2013
    Publication date: February 13, 2014
    Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Barbara B. Kahn, Qin Yang, Tim Graham, Odile Peroni
  • Publication number: 20140045933
    Abstract: Provided are methods, compositions, systems, and kits for treating metabolic syndrome or a disorder associated with metabolic syndrome, e.g., obesity, dyslipidemia, and/or a diabetic condition, comprising administering systemically to a subject one or more compounds of the Formula (I) and/or (II): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein, L, R1; R2, Z, X, A and B are defined herein.
    Type: Application
    Filed: January 18, 2012
    Publication date: February 13, 2014
    Applicant: Terakine Therapeutics, Inc.
    Inventor: Murat V. Kalayoglu
  • Patent number: 8642658
    Abstract: Compounds, methods, uses, compositions, kits and packages for the prevention and/or treatment of neural injury or a neurodegenerative disease, based on the use of a retinoic acid derivative, such as fenretinide, and/or analogs, derivatives, pro-drugs, precursors thereof, and/or salts thereof, are described.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: February 4, 2014
    Assignee: Royal Institution for the Advancement of Learning/McGill University
    Inventors: Danuta Radzioch, Samuel David, Ruben Lopez-Vales, Thomas Skinner
  • Patent number: 8618086
    Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: December 31, 2013
    Assignee: Duke University
    Inventors: Mitchell Anthony deLong, John McMillan McIver, Robert Scott Youngquist
  • Patent number: 8618169
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of conditions such as central or peripheral nervous system disorders through the modulation of potassium ion flux through voltage-dependent potassium channels and/or depressing cortical and/or peripheral neuron activity are disclosed. Novel derivatives of N-phenylanthranilic acid are also disclosed.
    Type: Grant
    Filed: March 20, 2012
    Date of Patent: December 31, 2013
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Bernard Attali, Asher Peretz
  • Patent number: 8618163
    Abstract: The invention provides well defined compounds having FPRL-1 agonist or antagonist activity. As such, the compounds of the invention are useful for treating a variety of ocular disorders.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: December 31, 2013
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, John E. Donello, Vidyasagar Vuligonda, Michael E. Garst
  • Patent number: 8614251
    Abstract: The invention provides a new crystalline form of agomelatine, preparation and use thereof. The X-ray powder diffraction diagram of the agomelatine crystalline form shows main peaks at the diffraction angles 2? 11.13°, 11.82°, 17.49°, 18.29°, 19.48°, 19.72°, 20.50°, 21.76°, 22.54°, 22.97°, 24.56°, 25.36°, 27.16° and 31.93°. Said new crystalline form is characterized by high purity, stability and good reproducibility, and thus is advantageous for the pharmaceutical formulation. In addition, the stability and solubility of said crystalline form are also superior over the several existing crystalline forms.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: December 24, 2013
    Assignee: Les Laboratories Servier
    Inventors: Hanbin Shan, Peng Zhang, Zhedong Yuan, Xudong Jiang, Yu Huang, Hubo Wang, Xufeng Cao, Xingdong Cheng, Xiong Yu
  • Patent number: 8609731
    Abstract: The invention relates to substituted tetrahydronaphthalenes and derivatives thereof, and also to the physiologically compatible salts and physiologically functional derivatives thereof, to preparation thereof, to medicaments comprising at least one inventive substituted tetrahydronaphthalene or derivative thereof, and to the use of the inventive substituted tetrahydronaphthalenes and derivatives thereof as medicaments.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: December 17, 2013
    Assignee: SANOFI
    Inventors: Lothar Schwink, Siegfried Stengelin, Matthias Gossel, Torsten Haack, Petra Lennig
  • Patent number: 8609684
    Abstract: A composition for increasing the bioavailability of Acetaminophen in humans and animals, comprising Acetaminophen, a first water soluble surfactant having a cloud point greater than about 37° C., a second water soluble surfactant having a cloud point greater than about 37° C., wherein a mixture of the first surfactant and the second surfactant comprises a cloud point less than about 37° C.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: December 17, 2013
    Assignee: PruGen IP Holdings, Inc.
    Inventor: Bhiku G. Patel
  • Patent number: 8604083
    Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: December 10, 2013
    Assignee: Wellstat Therapeutics Corporation
    Inventors: Shalini Sharma, Reid W. Von Borstel, Kirvin L. Hodge, Michael K. Bamat, Stephen D. Wolpe
  • Publication number: 20130303473
    Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.
    Type: Application
    Filed: November 10, 2011
    Publication date: November 14, 2013
    Applicant: NOVALIQ GmbH
    Inventor: Clive G. Wilson
  • Publication number: 20130289034
    Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.
    Type: Application
    Filed: June 21, 2013
    Publication date: October 31, 2013
    Inventors: Orion D. JANKOWSKI, Kieron E. WESSON, Paul MOLLARD, William D. SHRADER
  • Patent number: 8563254
    Abstract: The present invention provides novel biomarkers, and methods of using said biomarkers, for assessing the efficacy of a treatment regimen for treating cancer in a subject, particularly for treating cancer via Hsp90 inhibition. The present invention also provides methods of identifying test agents capable of treating cancer, particularly in the case of cancers characterized by high levels of IL-8.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: October 22, 2013
    Assignee: Novartis AG
    Inventors: Michaela Bowden, Alan Buckler, Chantale T. Guy
  • Patent number: 8551916
    Abstract: The present invention provides a method for obtaining O/W emulsions by emulsifying various to-be-emulsified material without the use of any organic solvent, and drying and making into powder the O/W emulsion. The invention relates to a method for producing an O/W emulsion including after preliminarily dispersing a to-be-emulsified material and an interfacially active organic compound in water, heating the preliminary dispersion to a temperature equal to or higher than the melting point of the to-be-emulsified material and equal to or higher than the phase transition temperature of a self-assembled product of the interfacially active organic compound in the absence of an organic solvent, and performing emulsification under a pressure.
    Type: Grant
    Filed: February 25, 2009
    Date of Patent: October 8, 2013
    Assignees: Hodogaya Chemical Co., Ltd., National Institute of Advanced Insustrial Science and Technology
    Inventors: Masumi Asakawa, Masaki Kogiso, Toshimi Shimizu, Atsushi Kisuno
  • Patent number: 8541466
    Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: September 24, 2013
    Assignee: Duke University
    Inventors: Mitchell Anthony DeLong, John McMillan McIver, Robert Scott Youngquist
  • Patent number: 8536229
    Abstract: The invention provides compounds of formula I wherein n, A, R, R?, R?, RO, X and Y are as defined in the description, and their preparation. The compounds of formula I are useful as pharmaceuticals.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: September 17, 2013
    Assignee: Novartis AG
    Inventors: Fabrizio Gasparini, Yves Auberson, Silvio Ofner, Terance W Hart, Kaspar Zimmerman
  • Patent number: 8530457
    Abstract: Treatment of lymphangioleiomyomatosis with the MEK1/2 inhibitor CI-1040 delayed the development of primary tumors and blocked the estrogen-induced lung metastases in treated animals. Such treatment also reduced the number of circulating ELT3 cells and decreased their lung colonization after intravenous injection.
    Type: Grant
    Filed: May 20, 2009
    Date of Patent: September 10, 2013
    Assignee: Fox Chase Cancer Center
    Inventors: Elizabeth Petri Henske, Jane Yu
  • Patent number: 8518999
    Abstract: The present invention provides compounds which are modulators of TNF-? signaling and methods of use thereof for treating a patient having a TNF-? mediated condition.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: August 27, 2013
    Assignee: Genzyme Corporation
    Inventors: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Fred Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
  • Publication number: 20130217691
    Abstract: A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of: (a) a ceramide-increasing retinoid such as fenretinide or a pharmaceutically acceptable salt thereof; and (b) at least one (and in certain embodiments at least two) compounds selected from the groups consisting of (i) a non-18 carbon chain length L-threo-sphinganine(s) or pharmaceuticeutically acceptable salt thereof, (ii) glucosylceramide or glucosyl(dihydro)ceramide synthesis inhibitor(s), and (iii) sphingomyelin or dihydrosphingomyelin synthase inhibitor(s). Preferred L-threo-sphinganines are of carbon chain length 17 carbons, 19 carbons and 20 carbons. A preferred glucosylceramide or glucosyl(dihydro)ceramide synthesis inhibitor is D-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol. A preferred sphingomyelin or dihydrosphingomyelin synthesis inhibitor is D-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol.
    Type: Application
    Filed: April 3, 2013
    Publication date: August 22, 2013
    Applicant: Texas Tech University System
    Inventor: Texas Tech University System
  • Patent number: 8513302
    Abstract: The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg/dL, and in persons with a cholesterol level over 200 mg/dL, by administering an inhibitor of soluble epoxide hydrolase (“sEH”). Optionally, a cis-epoxyeicosantrienoic acid (“EET”) can be administered with the sEH inhibitor. The invention further provides for using EETs in conjunction with one or more sEH inhibitors to reduce hypertension, and for compositions of EETs coated with a material insoluble in an acid of pH 3 but soluble in a solution with a pH of 7.4 or higher.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: August 20, 2013
    Assignee: The Regents of the University of California
    Inventors: Bruce D. Hammock, Takaho Watanabe, Seung-Jin Ma, Susan E. Bennett, Judith S. Stern, Christophe Morisseau, In-Hae Kim
  • Patent number: 8513307
    Abstract: Novel N-phenylacetamide compounds of formula (I): and cosmetic and pharmaceutical compositions containing same are useful for treating disorders of the sebaceous gland, e.g., acne, or have cosmetic applications.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: August 20, 2013
    Assignee: Galderma Research & Development
    Inventor: Thibaud Portal
  • Publication number: 20130190296
    Abstract: Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Tip-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating apoptosis and/or necrosis, and related methods for the treatment of diseases, including cancers such as lung, breast, colon, and/or prostate cancers as well as other diseases, such as benign prostatic hyperplasia, that are associated with Trp-p8 expression.
    Type: Application
    Filed: November 20, 2012
    Publication date: July 25, 2013
    Applicant: Dendreon Corporation
    Inventor: Dendreon Corporation
  • Patent number: 8486916
    Abstract: It is intended to find novel pharmaceutical use of sphingomyelin and to provide preventive or therapeutic agents for various diseases as well as a food and drink product and feed comprising any of these agents. The present invention provides a pharmaceutical agent which contains sphingomyelin as an active ingredient and is any of the following agents: 1) a sialomucin secretion promoter, 2) an agent for preventing drunken sickness (hangover), 3) an antiallergic agent, 4) an antioxidant, 5) an agent for defending against infection, 6) a hair growth agent, 7) a therapeutic agent for demyelinating disease, 8) an anti-pigmentation agent, 9) an anti-inflammatory agent, and 10) an agent for improving learning ability. The present invention also provides a food and drink product or feed, characterized by comprising the agent. It is preferred that the sphingomyelin should be derived from milk.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: July 16, 2013
    Assignee: Megmilk Snow Brand Co., Ltd.
    Inventors: Ken Kato, Susumu Miura, Leo Tanaka, Hiroshi Ueno, Noriko Ueda, Yuko Haruta, Toshimitsu Yoshioka
  • Publication number: 20130172388
    Abstract: Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof: wherein: R1 and R2 are independently H, alkyl, or alkenyl; R3 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; R4 and R5 are independently a bond, alkylenyl, or alkenylenyl; each R6 and R7 is independently selected from the group consisting of OH, F, Cl, Br, I, (C1-C6)alkyl, alkoxy, amino, COOH, CONH2, SO3H, PO3H2, CN, SH, NO2 and CF3; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.
    Type: Application
    Filed: December 14, 2012
    Publication date: July 4, 2013
    Applicant: University of Pittsburgh -- Of the Commonwealth System of Higher Education
    Inventor: University of Pittsburgh -- Of the Commonwealth System of Higher Education
  • Patent number: 8476255
    Abstract: Provided herein are novel, stilbene like compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, metabolites, prodrugs, solvates, pharmaceutically acceptable salts and compositions thereof. These compounds can inhibit HDACs and are useful as a therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, autoimmune diseases, skin diseases, infections, inflammation, etc.
    Type: Grant
    Filed: October 8, 2008
    Date of Patent: July 2, 2013
    Assignee: Orchid Chemicals & Pharmaceuticals Limited
    Inventors: Sridharan Rajagopal, Virendra Kachhadia, Thanasekaran Ponpandian, Abdul Raheem Keeri, Umamaheswari Mani, Suresh Rathinasamy, Praveen Rajendran, Kamaraj Mani, Balaji Ramachandran, Punthalir Narayanaswamy, Sriram Rajagopal
  • Patent number: RE44339
    Abstract: Cooling compounds are provided having the formula: wherein, m is 0 or 1, Y and Z are selected independently from the group consisting of H, OH, C1-C4 straight or branched alkyl, and a C1-C4 straight or branched alkoxy, X is (CH2)n—R, where n is 0 or 1 and R is a group with non-bonding electrons, with the provisos that: (a) when Y and Z are H, X is not F, OH, MeO or NO2 in the 4-position and is not OH in the 2 or 6-position (b) when Y or Z is H then X, Y and Z are such that (i) the groups in the 3- and 4-positions are not both OMe, (ii) the groups in the 4- and 5-positions are not both OMe, (iii) the groups in 3- and 5-positions are not OMe if the group in the 4-position is OH, and (iv) the groups in the 3- and 5-positions are not OH if the group in the 4-position is methyl.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: July 2, 2013
    Assignee: Givaudan S.A.
    Inventors: Christophe C. Galopin, Pablo Victor Krawec, Jay Patrick Slack, Lori W. Tigani